title: Resistance in the Ribosome: RUNX1, pre-LSCs, and HSPCs.
abstract: Therapeutic targeting of pre-leukemic stem cells (pre-LSCs) may be a viable strategy to eradicate residual disease and prevent leukemia relapse. Now in Cell Stem Cell, Cai et al. (2015) show that loss-of-function mutations in RUNX1 reduce ribosome biogenesis and provide pre-LSCs a selective advantage over normal hematopoietic cells through increased stress resistance.
authors.affiliation: Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
authors.forename: Kyoko
authors.initials: K
authors.lastname: Ito
authors.affiliation: Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Albert Einstein Cancer Center and Einstein Diabetes Research Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA. Electronic address: keisuke.ito@einstein.yu.edu.
authors.forename: Keisuke
authors.initials: K
authors.lastname: Ito
mesh_terms: D000818:Animals; D050676:Core Binding Factor Alpha 2 Subunit / Q000172:deficiency*; D006412:Hematopoietic Stem Cells / Q000378:metabolism*; D006801:Humans; D001678:Organelle Biogenesis; D012270:Ribosomes / Q000378:metabolism*
chemical_list: D050676:Core Binding Factor Alpha 2 Subunit